Clinical Trial Finder

• Restore CFTR FunctionEnrolling

  RESTORE-CF: Phase 1/2 study of MRT5005 drug in adults with cystic fibrosis (Parts A, B and B Expansion) , protocol number Translate Bio MRT5005-101

  This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of different doses of the nebulized drug MRT5005 in adults with CF.

  • Age:

    18 Years and Older

  • Mutation(s):

    Mutation Requirement

  • FEV1% Predicted:

    50 to 90%

  • Number of Visits:

    21

  • Length of Participation:

    1 years

• Anti-InflammatoryEnrolling

  Study to evaluate CB-280 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa , protocol number Calithera CX-280-202

  This study will look at the safety and tolerability of CB-280, an oral drug taken twice a day intended to treat infections in the lung and reduce inflammation. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    6

  • Length of Participation:

    2 months

• Anti-InfectiveEnrolling

  ABATE: Study to evaluate IV gallium in adults with cystic fibrosis who have nontuberculous mycobacteria (NTM) , protocol number ABATE-IP-18

  This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of IV gallium, a drug intended to treat infections in the lung.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25% or greater

  • Number of Visits:

    8

  • Length of Participation:

    20 weeks

• Nutritional-GIEnrolling

  OPTION 2: Study of AzurRX MS1819 in enteric capsules in adults with cystic fibrosis and exocrine pancreatic insufficiency , protocol number AzurRX AZ-CF2002

  This study will look at the safety and effectiveness of the drug MS1819 in enteric capsules as a pancreatic enzyme replacement therapy (PERT).

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    30% or greater

  • Number of Visits:

    10

  • Length of Participation:

    8 weeks

• ObservationalEnrolling

  Rare mutation cell collection (RARE) , protocol number RARE-OB-16

  This study is taking place at six regional care centers across the U.S. Researchers will collect and make available for study cells from people with rare CFTR mutations.

  • Age:

    12 Years and Older

  • Mutation(s):

    One Copy F508del or No Copies F508del

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    1

  • Length of Participation:

    2 days

• OtherEnrolling

  Study of SPI-1005 in people with CF ages 18 and older , protocol number Sound Pharma SPI-3005-501.2

  This study will test the safety and tolerability of SPI-1005, a drug intended to prevent and treat hearing loss caused by aminoglycosides.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    6

  • Length of Participation:

    49 days

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.